Linking research minds to global markets
A nexus for innovation, entrepreneurial educational models, management of intellectual property, and industries.
Learn more
Licensing Opportunities
Explore the technologies we have available for licensing and commercialization
Discover Technology
Previous slide
Next slide


Join the ACTIVE Program: Accelerating Healthcare Entrepreneurship in Arkansas

Empowering Arkansas entrepreneurs in healthcare and health tech. Receive comprehensive support and networking opportunities to accelerate your venture. Apply now to join the 2024 cohort and shape the future of healthcare entrepreneurship. 

Blog Banner for Website Content


ARHVA's Funding Opportunity

AR Health Ventures Accelerator (ARHVA) is seeking innovative proposals for therapeutic development. The program aims to accelerate scientific discoveries into practical therapies, bridging the gap between research and commercialization. Open to all UAMS employees. Deadline: September 29, 2023.

Recent technology:

Inhibition of dendritic cell-driven regulatory T cell activation and potentiation of tumor antigen-specific T cell responses by interleukin-15 and MAP kinase inhibitor

The invention involves the discovery that if dendritic cells loaded with a tumor antigen are cultured in interleukin-15 (IL-15), or if T cells activated by the dendritic cells are cultured in IL-15, Treg activity that is specific for the tumor antigen is reduced. This reduction in Treg activity results in an increase in anti-tumor immune response. Another embodiment of the invention involves the discovery that incubating dendritic cells with a MAP kinase inhibitor in combination with IL-15 gives synergistic benefits when the dendritic cells are used to activate T cells. Dendritic cell and T cell compositions incubated with IL-15 or a MAP kinase inhibitor are provided.

See More »

Methods of protecting against neurodegeneration

The disclosure provides a method of preventing or reducing protein aggregates using combretastatin-A4 (CA4) or an analog thereof. The disclosure also provides methods of reducing the risk, delaying the onset, delaying or slowing the progression, or reversing the signs or symptoms of a neurodegenerative (or other age-progressive) disease using a combretastatin-A4 (CA4) or an analog thereof. The combretastatin-A4 (CA4) or an analog thereof may bind glial fibrillary acidic protein (GFAP). The combretastatin-A4 (CA4) or an analog thereof is described by compounds of Formula (I).

See More »


BioVentures was established as a formal outgrowth of the University of Arkansas for Medical Sciences‘ (UAMS) interest in promoting a biomedical technology industry for Arkansas and translating its research into products that benefit human health.

UAMS established BioVentures to maximize global, industrial interaction with the University of Arkansas faculty, as well as to facilitate technology transfer, the development of startup companies that are based on technology developed at UAMS, and contributions to Arkansas’ economic development.

BioVentures links the research minds at UAMS to global markets in order to advance Arkansas’ scientific and economic development.

Get In Touch

Meet Us

401 South Cedar Street Little Rock, Arkansas 72205

Call Us

(501) 686-6696

Email Us